Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data
ECONOMY & POLICY

Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA).

MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism.

Key Publication Highlights:

Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more

Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA). MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism. Key Publication Highlights: Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Next Story
Infrastructure Urban

SCLR Extension Nears Completion Linking BKC With Signal-Free Route

The Santacruz-Chembur Link Road (SCLR) extension towards Bandra-Kurla Complex (BKC) via the Mumbai University campus has entered its final stage, bringing motorists closer to a direct, signal-free connection between the Western Express Highway and the city’s commercial district. The elevated connector is being built as an arm from the SCLR alignment and will link the western suburbs with BKC without surface signals. The link is designed to reduce journey times for commuters travelling from the western suburbs to BKC and to improve access to eastern Mumbai. By carrying through traffic above s..

Next Story
Infrastructure Transport

Raiganj MP Seeks Bengal Only Highway Link To Siliguri

Raiganj Member of Parliament Kartik Chandra Paul met Union Minister for Road Transport and Highways Nitin Gadkari in New Delhi to press for a new stretch of national highway in North Dinajpur district. He urged approval for a Bengal-to-Bengal link that would connect National Highways 12 and 27 to allow vehicles bound for Siliguri to avoid the current route through Kishanganj in neighbouring Bihar. He also submitted a proposed alignment of the new road to the ministry for consideration. At present vehicles from Raiganj travel along NH-12 and join NH-27 at Purnia More in Dalkhola, a route that p..

Next Story
Infrastructure Transport

Airport Kilambakkam Metro Line To Be Extended To Chengalpattu

Chennai Metro Rail (CMRL) has invited tenders for two detailed project reports that would extend its rail network to Chengalpattu in the south and extend Corridor-5 to Wimco Nagar in the north as part of a second wave of expansion beyond the operator's corridors under construction. The move signals an acceleration of planning for suburban links and interchange nodes. The larger of the two studies covers a roughly 27km extension from the planned Kilambakkam metro station to Chengalpattu under Corridor-1, Phase I. CMRL floated the tender at an estimated cost of Rs 21.6 mn. The proposed line woul..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement